C24-Ceramide
Based on 1 Customer Validation
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 34435-05-7
- Formule: C42H83NO3
- Masse moléculaire:650.11
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Lipid Compound Library
HY-L043
-
Oxygen Sensing Compound Library
HY-L045
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Pain-Related Compound Library
HY-L139
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Mouse Metabolite Compound Library
HY-L217
-
Lactylation Compound Library
HY-L249
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
189.4 μM
Compound: 2
|
Anticancer activity against human HepG2 cells assessed as reduction in cell survival
Anticancer activity against human HepG2 cells assessed as reduction in cell survival
|
[PMID: 38086468] |
C24-Ceramide (100 μg/mL; 48 h) significantly promotes cell proliferation and migration in human keratinocytes (HaCaT)[2].
C24-Ceramide (500 μg/mL; 24 h) activates AKT and ERK1/2 signaling pathways[2].
C24-Ceramide (100 nM; 12 h) promotes cell proliferation and migration in gallbladder cancer cells (GBC-SD, NOZ) by binding to PIP4K2C and activating mTOR signaling, while C6-Ceramide competitively inhibited this effect[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
C24-Ceramide (10 mg/kg; dietary supplementation; once daily; 3 weeks) promotes the growth of gallbladder cancer (GBC-SD cells) in a nude mouse subcutaneous xenograft tumor model, as evidenced by increased tumor volume, weight, and the proportion of Ki-67 positive cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male HR-1 hairless mice (6-week-old, 18-20 g), full-thickness skin wound model[2]
-
Dosage:4.4 μg C24-Ceramide per dose (formulated as C24-LNP in deionized water)
-
Administration:Topical application (10 μL of 1 mg/mL C24-LNP) daily for 10 days
-
Result:Significantly accelerated wound closure.
Enhanced re-epithelialization, increased fibroblast proliferation, and improved collagen deposition in the dermis, as confirmed by Masson’s trichrome staining.
Activated AKT and ERK1/2 signaling pathways in wound tissues, promoting cell proliferation and migration.
-
Animal Model:Nude mice subcutaneous xenograft model with GBC-SD cells[3]
-
Dosage:10 mg/kg
-
Administration:Daily oral administration via dietary addition for 3 consecutive weeks
-
Result:Significantly increased tumor size and Ki-67 reactivity in xenograft sections, indicating enhanced cell proliferation.
Promoted hepatic metastasis, with higher incidence and size of metastatic lesions compared to control.
Activated mTOR signaling through binding to PIP4K2C, which was antagonized by C6-Ceramide co-treatment.
Chemical Information
-
CAS No. 34435-05-7
-
Appearance Solid
-
Masse moléculaire 650.11
-
Formule C42H83NO3
-
Color White to off-white
-
SMILES
CCCCCCCCCCCCCCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
THF : 25 mg/mL (38.46 mM; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ventura AE, et al. Lipid domain formation and membrane shaping by C24-ceramide. Biochim Biophys Acta Biomembr. 2020 Oct 1;1862(10):183400. [Content Brief]
[2]. Lee JH, et al. C24 Ceramide Lipid Nanoparticles for Skin Wound Healing. Pharmaceutics. 2025 Feb 12;17(2):242. [Content Brief]
[3]. Zhang Y, et al. C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation. Hepatology. 2021 Feb;73(2):692-712. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| THF | 1 mM | 1.5382 mL | 7.6910 mL | 15.3820 mL | 38.4550 mL |
| 5 mM | 0.3076 mL | 1.5382 mL | 3.0764 mL | 7.6910 mL | |
| 10 mM | 0.1538 mL | 0.7691 mL | 1.5382 mL | 3.8455 mL | |
| 15 mM | 0.1025 mL | 0.5127 mL | 1.0255 mL | 2.5637 mL | |
| 20 mM | 0.0769 mL | 0.3846 mL | 0.7691 mL | 1.9228 mL | |
| 25 mM | 0.0615 mL | 0.3076 mL | 0.6153 mL | 1.5382 mL | |
| 30 mM | 0.0513 mL | 0.2564 mL | 0.5127 mL | 1.2818 mL |
C24-Ceramide Related Classifications
HY-134508 Related Classifications
Powered by Bioz